GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Race Oncology Ltd (ASX:RAC) » Definitions » 5-Year EBITDA Growth Rate

Race Oncology (ASX:RAC) 5-Year EBITDA Growth Rate : -23.80% (As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Race Oncology 5-Year EBITDA Growth Rate?

Race Oncology's EBITDA per Share for the six months ended in Dec. 2024 was A$-0.03.

During the past 3 years, the average EBITDA Per Share Growth Rate was -30.80% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -23.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Race Oncology was 21.70% per year. The lowest was -32.10% per year. And the median was -18.10% per year.

Competitive Comparison of Race Oncology's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, Race Oncology's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Race Oncology's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Race Oncology's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Race Oncology's 5-Year EBITDA Growth Rate falls into.


;
;

Race Oncology 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Race Oncology  (ASX:RAC) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Race Oncology 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Race Oncology's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Race Oncology Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Race Oncology Ltd (ASX:RAC) » Definitions » 5-Year EBITDA Growth Rate
Comparable Companies
ASX:IMU ASX:ALA ASX:PAR ASX:DXB ASX:ACW ASX:AGN ASX:RCE ASX:EZZ ASX:ATH ASX:LTP VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
1 Macquarie Place, Level 36, Gateway, Sydney, NSW, AUS, 2000
Website
https://www.raceoncology.com
Race Oncology Ltd is a clinical stage biopharmaceutical company with a mission to be at the heart of cancer care. Its asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a clinical history with demonstrated therapeutic benefits in both adult and pediatric patients, a well-characterized safety profile, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin. It has reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations, where Race can deliver cardioprotection and enhanced anticancer activity in solid tumors.